Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series

Demisse, Rahel, Damle, Neha, Kim, Edward, Gong, Jun, Fakih, Marwan, Eng, Cathy, Oesterich, Leslie, McKenny, Madison, Ji, Jingran, Liu, James, Louie, Ryan, Tam, Kit, Gholami, Sepideh, Halabi, Wissam, Monjazeb, Arta, Dayyani, Farshid, Cho, May (July 2020) Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. Journal of the National Comprehensive Cancer Network : JNCCN, 18 (7). pp. 798-804. ISSN 1540-1405

URL: https://www.ncbi.nlm.nih.gov/pubmed/32634770
DOI: 10.6004/jnccn.2020.7558

Abstract

Treatment options for locally advanced rectal cancer have continued to consist largely of chemotherapy, chemoradiation, and/or surgical resection. For patients who are unable to undergo these therapeutic modalities or who do not to experience a response to them, treatment options are limited. We report 3 cases of mismatch repair-deficient (dMMR) locally advanced adenocarcinoma of the rectum that showed significant response with neoadjuvant immunotherapy-based systemic treatment. The first patient was not eligible for standard therapy because of a history of radiotherapy to the prostate with concurrent comorbidities and therefore received single-agent pembrolizumab. The second patient did not respond to total neoadjuvant chemoradiation and subsequently received combined nivolumab and ipilimumab. The third patient had a known family history of Lynch syndrome and presented with locally advanced rectal cancer and a baseline carcinoembryonic antigen level of 1,566 ng/mL. She was treated using neoadjuvant pembrolizumab and FOLFOX (folinic acid, fluorouracil, oxaliplatin). In this small series, we suggest that single-agent and combined-modality neoadjuvant immunotherapy/chemotherapy appear to be safe and effective treatment options for patients with (dMMR) locally advanced rectal cancer. Our findings encourage further studies to investigate the role of neoadjuvant immunotherapy as a viable treatment strategy in this population.

Item Type: Paper
Subjects: diseases & disorders > cancer
diseases & disorders
diseases & disorders > neoplasms
diseases & disorders > cancer > cancer types > colon cancer
diseases & disorders > cancer > cancer types > colon cancer
diseases & disorders > cancer > drugs and therapies > Immunotherapy
diseases & disorders > cancer > cancer types
CSHL Authors:
Communities: CSHL labs > Gholami Lab
SWORD Depositor: CSHL Elements
Depositing User: CSHL Elements
Date: July 2020
Date Deposited: 05 Oct 2023 17:35
Last Modified: 29 Jan 2024 21:05
Related URLs:
URI: https://repository.cshl.edu/id/eprint/41134

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving